Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PERTH, WESTERN AUSTRALIA, AUG. 24, 2026 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP. (NOVO OR THE COMPANY) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) IS PLEASED TO ANNOUNCE THE RELEASE OF ITS UPDATED CORPORATE PRESENTATION, NOW AVAILABLE ON THE COMPANY'S WEBSITE.

NOVO RESOURCES RELEASES UPDATED CORPORATE PRESENTATION

MCLEAN, VA.--(BUSINESS WIRE)--CRUX, A BENEFITS OPERATING SYSTEM THAT CONNECTS EMPLOYERS, PHARMACEUTICAL MANUFACTURERS, AND BENEFIT SOLUTION PROVIDERS, TODAY ANNOUNCED A COLLABORATION WITH GLOBAL HEALTHCARE COMPANY NOVO NORDISK TO EXPAND AFFORDABLE AND SIMPLIFIED ACCESS TO AUTHENTIC ANTI-OBESITY MEDICATIONS (AOMS) LIKE WEGOVY FOR EMPLOYER HEALTH PLANS ACROSS THE UNITED STATES. THROUGH AN ALTERNATIVE PHARMACY BENEFIT STRUCTURE, THE AGREEMENT WILL ALLOW CRUX TO DELIVER A DEDICATED CARVE-OUT SOLUT.

CRUX COLLABORATES WITH NOVO NORDISK TO OFFER ACCESS TO WEGOVY AND OTHER OBESITY MANAGEMENT MEDICATIONS

PERTH, WEST AUSTRALIA, JULY 22, 2026 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP.(NOVO OR THE COMPANY) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) IS PLEASED TO ANNOUNCE THE RELEASE OF ITS UPDATED CORPORATE PRESENTATION, NOW AVAILABLE ON THE COMPANY'S WEBSITE. THE NEW PRESENTATION OUTLINES NOVO'S STRATEGIC PRIORITIES, EXPLORATION RESULTS, PROJECT ADVANCEMENTS, AND NEAR-TERM CATALYSTS.

BAGSVRD, DENMARK, 11 JUNE 2026  NOVO NORDISK A/S HAS IDENTIFIED AN IT SECURITY INCIDENT INVOLVING UNAUTHORISED ACCESS TO A LIMITED NUMBER OF INTERNAL IT SYSTEMS. UPON LEARNING OF THE INCIDENT, WE LAUNCHED AN INVESTIGATION WITH THE ASSISTANCE OF EXTERNAL CYBERSECURITY EXPERTS, AND WE ARE IN CONTACT WITH THE RELEVANT AUTHORITIES.

NOVO NORDISK A/S: IT SECURITY INCIDENT AT NOVO NORDISK

APPROVAL IS BASED ON RESULTS FROM THE OASIS 4 TRIAL, WHICH INVESTIGATED SEMAGLUTIDE TABLETS 25 MG IN ADULTS LIVING WITH OBESITY AND OVERWEIGHT VERSUS PLACEBO IN ADDITION TO DIET AND EXERCISE SEMAGLUTIDE TABLETS WILL BE AVAILABLE AS A ONCE-DAILY TREATMENT, AN ALTERNATIVE TO WEEKLY INJECTIONS FOR ADULTS LIVING WITH OBESITY OR OVERWEIGHT WITH A WEIGHT-RELATED CONDITION, ALONGSIDE DIET AND EXERCISE AFTER THIS APPROVAL FROM THE UK'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA), NOVO NORDISK ANTICIPATES WEGOVY PILL WILL BE AVAILABLE VIA PRIVATE PRESCRIPTION WITHIN WEEKS BAGSVRD, DENMARK, 11 JUNE 2026  WEGOVY PILL, THE NEW DAILY WEIGHT MANAGEMENT TABLET, HAS BEEN APPROVED IN THE UK AS AN ADJUNCT TO A REDUCED-CALORIE DIET AND INCREASED PHYSICAL ACTIVITY, OFFERING A FIRST-OF-ITS-KIND ALTERNATIVE TO INJECTABLE TREATMENTS FOR ADULTS. THE UK'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) HAS APPROVED WEGOVY PILL (SEMAGLUTIDE TABLETS), AN ORAL GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST LICENSED FOR WEIGHT MANAGEMENT IN ADULTS LIVING WITH OBESITY (INITIAL BODY MASS INDEX (BMI) 30 KG/M2), OR OVERWEIGHT (BMI 27 KG/M2 TO

NOVO NORDISK: WEGOVY PILL (SEMAGLUTIDE TABLETS) BECOMES FIRST DAILY GLP-1 WEIGHT-LOSS PILL APPROVED IN THE UK

BAGSVRD, DENMARK, 8 JUNE 2026 ON 6 MAY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

NOVO NORDISK IS LAUNCHING WEGOVY PILL IN THE UAE, THE FIRST COUNTRY OUTSIDE THE US, TO MAKE THE WEGOVY PILL AVAILABLE TO PEOPLE LIVING WITH OBESITY

WEGOVY PILL LAUNCHES IN THE UAE AS NOVO NORDISK EXPANDS GLOBAL ACCESS TO OBESITY CARE

BAGSVRD, DENMARK, 1 JUNE 2026  ON 6 MAY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

NOT FOR RELEASE TO US WIRE SERVICE OR DISTRIBUTION IN THE UNITED STATES PERTH, AUSTRALIA, MAY 28, 2026 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP. (NOVO OR THE COMPANY) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) IS PLEASED TO ANNOUNCE THAT TRANCHE 2 OF THE PLACEMENT IT ANNOUNCED ON 24 AND 26 FEBRUARY 2026 (VANCOUVER)/25 AND 26 FEBRUARY 2026 (PERTH) (PLACEMENT) COMPLETED TODAY FOLLOWING SHAREHOLDER APPROVAL THAT WAS RECEIVED AT THE COMPANY'S ANNUAL GENERAL MEETING (AGM) HELD ON 21 MAY 2026 (VANCOUVER)/22 MAY 2026 (PERTH). THE COMPANY RECEIVED GROSS PROCEEDS OF ~C$1.93M (APPROXIMATELY A$1.95M) THROUGH THE ISSUE OF THE FOLLOWING SECURITIES UNDER TRANCHE 2 OF THE PLACEMENT: ~8.0M UNITS AT C$0.10 PER UNIT TO INVESTORS IN CANADA (WITH EACH UNIT COMPRISING ONE COMMON SHARE OF NOVO (EACH, A COMMON SHARE) AND ONE-HALF (0.5) COMMON SHARE PURCHASE WARRANT (UNIT)); AND ~10.9M CHESS DEPOSITORY INTERESTS (CDIS) AT A$0.105 PER CDI TO INVESTORS OUTSIDE OF CANADA, TOGETHER WITH THE RIGHT TO RECEIVE ONE OPTION TO PURCHASE ONE CDI (EACH AN OPTION) FOR EVERY TWO CDI'S SUBSCRIBED FOR UNDER THE PLACEMENT, EACH OPTION ENTITLING THE HOLDER TO PURCHASE ONE CDI AT A PRICE OF A$0.15 FOR A PERIOD OF THREE YEARS (WITH ONE COMMON SHARE UNDERLYING EACH CDI).

COMPLETION OF TRANCHE 2 OF PLACEMENT

BAGSVRD, DENMARK, 26 MAY 2026  ON 6 MAY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

Novo Nordisk A/S

NVO

Price

Financial Reports

No items found.

Press Releases

Novo Nordisk A/S

NVO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVO